OCUGEN, INC. Increase (Decrease) in Contract with Customer, Liability
OCUGEN, INC. (OCGN) reported Increase (Decrease) in Contract with Customer, Liability of $10.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2019-08-09
- OCUGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2018-09-30 was $0.00.
- OCUGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2018-06-30 was $0.00.
- OCUGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2018-03-31 was $10.00M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-08-09 | $10.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $10.00M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $10.00M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |